Connexios Life Science Pvt Ltd. Release: Preclinical Data on CNX-011-67 was Presented at the 71st Scientific Sessions of the American Diabetes Association Meeting San Diego, CA, June 24-28, 2011

27 June 2011 – Connexios Life Sciences, Bangalore, a research and development company focused on developing novel therapeutics for metabolic disorders today announced that preclinical data on CNX-011-67, a highly potent and selective GPR40 agonist, was presented at the 71st Scientific Sessions of the American Diabetes Association taking place from 24 – 28 June 2011 at San Diego, California. CNX-011-67 is a novel small molecule candidate that, by acting on the pancreatic beta cells, will enhance glucose sensitivity, insulin secretion and reduce metabolic stress.

The data presented in the meeting adds to the growing understanding of the critical role played by GPR40 for the health and function of the pancreatic beta cell. The two-pronged impact of GPR40 activation by CNX-011-67 results in simultaneously enhancing insulin content and glucose stimulated insulin secretion while significantly reducing metabolic stress in the beta cell and consequent apoptosis. CNX-011-67 is being developed by Connexios as an oral anti-diabetic that can potentially be positioned as a key early therapy for diabetics that can protect against beta cell decline and delay the onset or progression of disease, while providing robust glycemic control.

The following abstract was accepted for the poster presentation at the 71st Scientific Sessions of the American Diabetes Association meeting:

Poster presentation

- CNX-011-67, A Novel Orally Available GPR40 Agonist, Enhances Glucose Stimulated Insulin Secretion (GSIS) and Significantly Reduces Fasting and Non-Fasting Hyperglycemia- Studies In Vitro And In a Preclinical Model of T2DM (Poster 31-LB in category 01-D Clinical Therapeutics/New Technology – Pharmacologic Treatment of Diabetes or its Complications. June 26th 12:00 PM – 2:00 PM)

About Connexios

Connexios is an innovation driven, early stage drug discovery and development company based on a unique Translational Network Biology approach. The company has developed a deep understanding of diseases of metabolism and T2DM in particular. Connexios is committed to discovering novel therapeutics for T2DM that go beyond purely glycemic endpoints to address the multiple pathologies that underlie disease across tissues.

The company has built a broad and innovative pipeline with best-in-class molecules that target both recently uncovered and completely novel targets. Connexios is privately funded, with over 180 employees and laboratories and offices in Bangalore, India.

For more information, contact:

Suri Venkatachalam - CEO

Phone: +91 80 41210672

e-mail – suri.venkatachalam@connexios.com

Shobha Vijayaraghavan – VP, Business Development

Phone: +91 80 42683999

e-mail – shobha.v@connexios.com

Stephanie Cuthbert

Associate Vice President

Financial Dynamics

Holborn Gate, 26 Southampton Buildings

London, WC2A 1PB

D +44 (0)20 3077 0458

M +44(0)7738 198 934

www.fd.com